REGENERON PHARMACEUT

REGN
Real-time Estimate Quote. Real-time Estimate  - 11/23 05:23:26 pm
522.145USD +0.66%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 7 8638 592
EBITDA1 3 4204 215
Operating profit (EBIT)1 2 2103 469
Operating Margin 28,1%40,4%
Pre-Tax Profit (EBT)1 2 4293 573
Net income1 2 1163 189
Net margin 26,9%37,1%
EPS2 18,528,7
Dividend per Share2 --
Last update 02/06/202011/23/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 --
Net Cash position1 5 7575 832
Leverage (Debt / EBITDA) -1,68x-1,38x
Free Cash Flow1 2 0002 752
ROE (Net Profit / Equities) 28,5%29,6%
Shareholders' equity1 7 42710 759
ROA (Net Profit / Asset) 15,9%21,9%
Assets1 13 27014 552
Book Value Per Share2 102146
Cash Flow per Share2 21,234,2
Capex1 430555
Capex / Sales 5,46%6,45%
Last update 02/06/202011/23/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 55 264 M $ -
Entreprise Value (EV) 49 432 M $ 45 019 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 18,2x 14,5x
Capitalization / Revenue 6,43x 5,32x
EV / Revenue 5,75x 4,76x
EV / EBITDA 11,7x 9,64x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,58x 2,63x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 40,4% 43,4%
Operating Leverage (Delta EBIT / Delta Sales) 6,15x 1,43x
Net Margin (Net Profit / Revenue) 37,1% 36,8%
ROA (Net Profit / Asset) 21,9% 26,3%
ROE (Net Profit / Equities) 29,6% 34,3%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   6,45% 5,73%
Cash Flow / Sales 42,0% 37,4%
Capital Intensity (Assets / Sales) 1,69x 1,40x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend